Kaye Spratt, PhD is Chief Regulatory Affairs Officer of Aspa Therapeutics, bringing 30 years of experience in the pharmaceutical industry, including over 5 years specializing in Regulatory Affairs. Her regulatory efforts have focused primary on the clinical development of rare pediatric and neurodegenerative disease. Prior to joining, BridgeBio Bene Therapy, she served as Senior Vice President of Regulatory Affairs at the clinical-stage gene therapy company Abeona Therapeutics, Inc where she secured US and Ex-US orphan designations, FastTrack, RMAT and Breakthrough designations for clinical stage product and secured Scientific Advice from local and national regulatory agencies. Earlier in her career, Dr. Spratt served as Nonclinical Director/Assay Development and Quality Control Director, with increasing responsibilities for over 17 years at Sangamo Therapeutics. At Sangamo she was a major contributor to early discovery and development for several IND candidates in multiple therapeutic areas. Dr. Spratt has a BS degrees in Biology from Langston University and a PhD in Microbiology/Molecular Biology from Meharry Medical College.